This week we look at gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and a gene therapy for spinal muscular atrophy.
Browsing: multiple sclerosis
The EMA has approved Gilenya® (fingolimod) for the treatment of children and adolescents with relapsing–remitting forms of multiple sclerosis.
This week we look at NurOwn® for multiple sclerosis, a combination therapy failing to meet primary endpoint for glioblastoma and warnings from the US FDA.
A new cellular immunotherapy that targets the Epsein–Barr virus could improve the symptoms and quality of life for individuals with multiple sclerosis.
At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
In this interview, we spoke with Bruce Trapp about how his team identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
Not able to attend ECTRIMS this year? You can catch up with all the action from today with our daily video, best of social media and poster highlights.
Today was the second day of ECTRIMS, with more fascinating talks and exciting posters. You can catch up on the highlights and headlines in our daily update.
Today was the first day of ECTRIMS 2018 and we’re excited to be attending! You can find a daily video update, photos from the day, poster highlights and more in our daily updates.
Novartis (Basel, Switzerland) have announced US FDA and EMA filing acceptance for siponimod, a new drug developed to treat secondary progressive multiple sclerosis in adults.